JAC Advance Access originally published online on July 15, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 52, 264-268
© 2003 The British Society for Antimicrobial Chemotherapy
Mediterranean visceral leishmaniasis in HIV-negative adults: a retrospective analysis of 64 consecutive cases (1995–2001)
1 I Division of Infectious Disease, D. Cotugno Hospital, Naples; 2 Division of Parasitology, D. Cotugno Hospital, Naples; 3 Department of Parasitology, Istituto Superiore di Sanità, Rome, Italy
Received 5 February 2003; returned 27 March 2003; revised 3 April 2003; accepted 28 May 2003
Aim: To evaluate in a retrospective analysis cases of Mediterranean visceral leishmaniasis (VL) diagnosed in HIV-negative adults during a 7-year period.
Materials and methods: Demographic data, previous or underlying diseases, clinical and laboratory features and therapeutic findings were considered.
Results: A total of 64 patients were included, of whom 10 (16%) had underlying diseases and two were pregnant. Fever and hepatosplenomegaly were the main presenting symptoms, whereas pancytopenia and an elevated erythrocyte sedimentation rate were observed in all cases. Smears from bone marrow aspirate were positive at microscopy in 62 cases (97%). Twenty-four patients received meglumine antimoniate (MA) given during 21 consecutive days (20 mg/kg per day), and 40 patients liposomal amphotericin B (l-AmB) given at days 1–5 and 10 (3 mg/kg per day). Both groups’ clinical and laboratory findings improved, but patients on l-AmB therapy had a faster recovery (85% on l-AmB therapy and 50% on MA therapy showed defervescence at day 5, P < 0.01). Treatment failures were observed in five cases, three (12%) on MA and two (5%) on l-AmB therapy. No significant toxicity was observed in patients treated with l-AmB, whereas three (12%) patients treated with MA showed electrocardiographic abnormalities.
Conclusions: l-AmB therapy may be considered the treatment of choice for any adult patients with Mediterranean VL, since it permits a faster recovery, has a lower incidence of side effects and is useful also in immunosuppressed patients.
Keywords: visceral leishmaniasis, liposomal amphotericin B, meglumine antimoniate, Leishmania infantum, treatment
* Correspondence address: I Division of Infectious Diseases, D. Cotugno Hospital, Via G. Quagliariello 54, 80131 Naples, Italy; E-mail: ppagliano{at}libero.it
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Pagliano, S. Costantini, L. Gradoni, F. S. Faella, A. Spasiano, G. Mascarella, L. Prossomariti, U. Fusco, and P. Ricchi Distinguishing Visceral Leishmaniasis from Intolerance to Pegylated Interferon-{alpha} in a Thalassemic Splenectomized Patient Treated for Chronic Hepatitis C Am J Trop Med Hyg, July 1, 2008; 79(1): 9 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pagliano, N. Carannante, M. Gramiccia, T. Ascione, G. Stornaiuolo, L. Gradoni, F. S Faella, and G. B Gaeta Visceral leishmaniasis causes fever and decompensation in patients with cirrhosis Gut, June 1, 2007; 56(6): 893 - 894. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bassetti, C. Pizzorni, L. Gradoni, V. Del Bono, M. Cutolo, and C. Viscoli Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab Rheumatology, November 1, 2006; 45(11): 1446 - 1448. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Di Nicuolo, P. Pagliano, S. Battisti, M. Starace, V. Mininni, V. Attanasio, and F. S. Faella Toscana Virus Central Nervous System Infections in Southern Italy J. Clin. Microbiol., December 1, 2005; 43(12): 6186 - 6188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pagliano, N. Carannante, M. Rossi, M. Gramiccia, L. Gradoni, F. S. Faella, and G. B. Gaeta Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature J. Antimicrob. Chemother., February 1, 2005; 55(2): 229 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. W. MURRAY TREATMENT OF VISCERAL LEISHMANIASIS IN 2004 Am J Trop Med Hyg, December 1, 2004; 71(6): 787 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cascio, L. di Martino, P. Occorsio, R. Giacchino, S. Catania, A. R. Gigliotti, C. Aiassa, C. Iaria, S. Giordano, C. Colomba, et al. A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience J. Antimicrob. Chemother., July 1, 2004; 54(1): 217 - 220. [Abstract] [Full Text] [PDF]
|
|